Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.
Ravandi
Farhad
F
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. fravandi@mdanderson.org
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000188:drug therapy* / Q000209:etiology*; D008495:Medical Oncology / Q000379:methods; D016609:Neoplasms, Second Primary / Q000188:drug therapy* / Q000209:etiology; D010087:Oxides / Q000627:therapeutic use; D014178:Translocation, Genetic; D016896:Treatment Outcome; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide